Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16). Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE